Bottle Design for Infant Weight Gain
(AB3 Trial)
Trial Summary
What is the purpose of this trial?
This study will use a 2 x 2 factorial design to test impact of two intervention strategies (bottle size and bottle opacity) on infant weight gain.
Do I have to stop my baby's current bottles for the trial?
Yes, you will need to stop using your current bottles and use the intervention bottles assigned during the study.
What data supports the effectiveness of the treatment involving different bottle designs for infant weight gain?
Is the bottle design for infant weight gain safe for use?
How does the bottle design treatment for infant weight gain differ from other treatments?
This treatment is unique because it explores how different bottle designs, such as clear versus opaque and small versus standard sizes, can influence infant feeding behaviors and weight gain. Unlike other treatments, it focuses on the physical characteristics of the bottle to potentially prevent overfeeding and promote healthier weight gain in infants.12345
Research Team
Charles T Wood, MD, MPH
Principal Investigator
Duke University
Eligibility Criteria
This trial is for caregivers of infants aged 3 days to 1 month, who speak English or Spanish, with newborns above the 3rd percentile in birth weight and born after at least 37 weeks of pregnancy. Caregivers must be over 18 and plan to use a specific local clinic. They need to agree to only use the study's bottles.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive interventions with different bottle sizes and opacities to assess impact on infant weight gain
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Clear Bottle (Behavioral Intervention)
- Opaque Bottle (Behavioral Intervention)
- Small Bottle Size (Behavioral Intervention)
- Standard Bottle Size (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
Mary E. Klotman
Duke University
Chief Executive Officer since 2017
MD from Duke University School of Medicine
Michelle McMurry-Heath
Duke University
Chief Medical Officer since 2020
MD from Duke University School of Medicine
National Institutes of Health (NIH)
Collaborator
Dr. Jeanne Marrazzo
National Institutes of Health (NIH)
Chief Medical Officer
MD from University of California, Los Angeles
Dr. Jay Bhattacharya
National Institutes of Health (NIH)
Chief Executive Officer
MD, PhD from Stanford University